Bionovate Technologies (BIIO) Stock Price & Analysis
BIIO Stock Chart & Stats
- Day’s Range
- $0.08 - $0.08
- 52-Week Range
- $0.01 - $12.45
- Previous Close
- $0.08
- Volume
- N/A
- Average Volume (3M)
- 89
- Market Cap
- $775
- Enterprise Value
- $238.16B
- Total Cash (Recent Filing)
- $0
- Total Debt (Recent Filing)
- $237.53K
- Price to Earnings (P/E)
- ―
- Beta
- 136.64
- Next Earnings
- N/A
- EPS Estimate
- N/A
- Next Dividend Ex-Date
- N/A
- Dividend Yield
- N/A
BIIO FAQ
What was Bionovate Technologies’s price range in the past 12 months?
What is Bionovate Technologies’s market cap?
When is Bionovate Technologies’s upcoming earnings report date?
Is Bionovate Technologies overvalued?
Does Bionovate Technologies pay dividends?
What is Bionovate Technologies’s EPS estimate?
How many shares outstanding does Bionovate Technologies have?
Which hedge fund is a major shareholder of Bionovate Technologies?
What is the TipRanks Smart Score and how is it calculated?
Company Description
Bionovate Technologies
Bionovate Technologies Corp. is a medical device enterprise dedicated to pioneering automated solutions for the treatment of age spots. Its core objective is to engineer a sophisticated, computer-driven system designed to precisely target and treat these blemishes on any area of the body. The firm plans to distribute these advanced systems globally, marketing them to healthcare providers and wellness centers. Founded in Cham, Switzerland, in 2010, the organization previously traded under the name MJP International Ltd. before adopting Bionovate Technologies Corp. in December 2017. Since October 7, 2020, the company has operated as an affiliated entity of Human Data AG.
- Sector
- Healthcare
- Industry
- Medical - Devices
- CEO
- Timothy Jones
- Employees
- 0
- Website
- bionovate.com
- Address
- Gewerbestrasse 10, Cham, ZG, 6330, CH
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 4 | 2 | 3 |
| Technical Analysis | 2 | 0 | 1 |
| Moving Averages | 2 | 2 | 2 |
